Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucchini, Matteo, Bianco, Assunta, Del Giacomo, Paola, De Fino, Chiara, Nociti, Viviana, Mirabella, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307994/
https://www.ncbi.nlm.nih.gov/pubmed/32593961
http://dx.doi.org/10.1016/j.msard.2020.102323
_version_ 1783548914249498624
author Lucchini, Matteo
Bianco, Assunta
Del Giacomo, Paola
De Fino, Chiara
Nociti, Viviana
Mirabella, Massimiliano
author_facet Lucchini, Matteo
Bianco, Assunta
Del Giacomo, Paola
De Fino, Chiara
Nociti, Viviana
Mirabella, Massimiliano
author_sort Lucchini, Matteo
collection PubMed
description The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.
format Online
Article
Text
id pubmed-7307994
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-73079942020-06-23 Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report Lucchini, Matteo Bianco, Assunta Del Giacomo, Paola De Fino, Chiara Nociti, Viviana Mirabella, Massimiliano Mult Scler Relat Disord Correspondence The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient. Elsevier B.V. 2020-09 2020-06-22 /pmc/articles/PMC7307994/ /pubmed/32593961 http://dx.doi.org/10.1016/j.msard.2020.102323 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Lucchini, Matteo
Bianco, Assunta
Del Giacomo, Paola
De Fino, Chiara
Nociti, Viviana
Mirabella, Massimiliano
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
title Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
title_full Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
title_fullStr Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
title_full_unstemmed Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
title_short Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
title_sort is serological response to sars-cov-2 preserved in ms patients on ocrelizumab treatment? a case report
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307994/
https://www.ncbi.nlm.nih.gov/pubmed/32593961
http://dx.doi.org/10.1016/j.msard.2020.102323
work_keys_str_mv AT lucchinimatteo isserologicalresponsetosarscov2preservedinmspatientsonocrelizumabtreatmentacasereport
AT biancoassunta isserologicalresponsetosarscov2preservedinmspatientsonocrelizumabtreatmentacasereport
AT delgiacomopaola isserologicalresponsetosarscov2preservedinmspatientsonocrelizumabtreatmentacasereport
AT definochiara isserologicalresponsetosarscov2preservedinmspatientsonocrelizumabtreatmentacasereport
AT nocitiviviana isserologicalresponsetosarscov2preservedinmspatientsonocrelizumabtreatmentacasereport
AT mirabellamassimiliano isserologicalresponsetosarscov2preservedinmspatientsonocrelizumabtreatmentacasereport

Ejemplares similares